CCCC

C 4 Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↑ 5/10
  • Momentum↓ 4/10
C 4 Therapeutics sales and earnings growth
CCCC Growth
Neutral
  • Revenue Y/Y↓ -10.57%
  • EPS Y/Y↓ 1.76%
  • FCF Y/Y↓ -32.83%
C 4 Therapeutics gross and profit margin trends
CCCC Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -395.50%
  • ROIC↓ -44.80%
C 4 Therapeutics net debt vs free cash flow
CCCC Risk
Great
  • Debt / Equity↓ 0.4
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

C 4 Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗